Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cartesian Therapeutics has claimed a phase 2b win for its BCMA-directed CAR-T therapy in generalized myasthenia gravis (gMG). But the biotech’s victory came on a primary endpoint it changed in May and ...
Cartesian Therapeutics updates on Descartes-08 trials in myasthenia gravis and lupus, with financial results highlighting $182.1 million in cash. Cartesian Therapeutics, Inc. has announced the ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Cartesian Therapeutics, Inc. (RNAC) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 9:30 AM EDTCompany ParticipantsCarsten Brunn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results